Sarcomatoid Renal Cell Carcinoma: Biological Features and Therapeutic Implications—A Narrative Review

TL;DR

This paper reviews the aggressive kidney cancer subtype sarcomatoid renal cell carcinoma, focusing on its biology and potential for immunotherapy treatment.

Contribution

The paper provides a comprehensive overview of sRCC's molecular and immune features, suggesting immunotherapy as a promising treatment approach.

Findings

sRCC has a highly inflamed tumor microenvironment linked to better response to immunotherapy.

Genomic alterations and immune profiles of sRCC are distinct from other renal cancer subtypes.

Immunotherapy integration may improve outcomes for sRCC patients.

Abstract

This review underscores the importance of recognizing sarcomatoid features in renal cell carcinoma, as this component significantly impacts prognosis and treatment strategies.

Sarcomatoid renal cell carcinoma (sRCC) is a rare and aggressive form of renal cancer characterized by poor prognosis and distinct biological features. Despite its clinical significance, there remains a knowledge gap regarding the comprehensive understanding of its molecular and therapeutic landscape. Recent studies provided an extensive overview of the clinical, pathological, and molecular characteristics of sRCC, highlighting its unique genomic alterations and immune profile. Notably, sRCC exhibits a highly inflamed tumor microenvironment, which correlates with increased responsiveness to immune checkpoint inhibitors.

Our findings suggest that integrating immunotherapy into the management of sRCC could enhance patient outcomes, paving the way for future research and clinical applications in this challenging cancer subtype.

Figures